Skip to main content
Journal cover image

Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.

Publication ,  Journal Article
Reist, CJ; Foulon, CF; Alston, K; Bigner, DD; Zalutsky, MR
Published in: Nucl Med Biol
May 1999

Monoclonal antibodies (MAbs) such as the anti-epidermal growth factor variant III (EGFRvIII) MAb L8A4 are rapidly internalized, which can lead to rapid loss of radioactivity from the tumor cell. The aim of this study was to evaluate the potential utility of N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate ([211At]SAPC) for labeling murine L8A4 with 211At. SAPC was synthesized by astatodestannylation of N-succinimidyl 5-tri-n-butylstannyl 3-pyridinecarboxylate and then coupled to L8A4 in approximately 50% yield. The affinity and immunoreactive fraction for 211At-labeled L8A4 were comparable to those obtained when the MAb was labeled with 131I via N-succinimidyl 5-[131I]iodo-3-pyridinecarboxylate (SIPC). Paired-label comparisons of the 211At- and 131I-labeled MAbs demonstrated similar internalization and catabolism by EGFRvIII-positive cells in vitro, and with the exception of the stomach, similar tissue distribution in athymic mice with EGFRvIII-expressing U87MGdeltaEGFR xenografts. These results suggest that SAPC may be a useful reagent for labeling L8A4, and possibly other internalizing proteins, with 211At.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nucl Med Biol

DOI

ISSN

0969-8051

Publication Date

May 1999

Volume

26

Issue

4

Start / End Page

405 / 411

Location

United States

Related Subject Headings

  • Tissue Distribution
  • Radioimmunotherapy
  • Nuclear Medicine & Medical Imaging
  • Neoplasms, Experimental
  • Mice, Inbred BALB C
  • Mice
  • Isotope Labeling
  • Humans
  • ErbB Receptors
  • Drug Stability
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reist, C. J., Foulon, C. F., Alston, K., Bigner, D. D., & Zalutsky, M. R. (1999). Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nucl Med Biol, 26(4), 405–411. https://doi.org/10.1016/s0969-8051(98)00120-6
Reist, C. J., C. F. Foulon, K. Alston, D. D. Bigner, and M. R. Zalutsky. “Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.Nucl Med Biol 26, no. 4 (May 1999): 405–11. https://doi.org/10.1016/s0969-8051(98)00120-6.
Reist CJ, Foulon CF, Alston K, Bigner DD, Zalutsky MR. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nucl Med Biol. 1999 May;26(4):405–11.
Reist, C. J., et al. “Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.Nucl Med Biol, vol. 26, no. 4, May 1999, pp. 405–11. Pubmed, doi:10.1016/s0969-8051(98)00120-6.
Reist CJ, Foulon CF, Alston K, Bigner DD, Zalutsky MR. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nucl Med Biol. 1999 May;26(4):405–411.
Journal cover image

Published In

Nucl Med Biol

DOI

ISSN

0969-8051

Publication Date

May 1999

Volume

26

Issue

4

Start / End Page

405 / 411

Location

United States

Related Subject Headings

  • Tissue Distribution
  • Radioimmunotherapy
  • Nuclear Medicine & Medical Imaging
  • Neoplasms, Experimental
  • Mice, Inbred BALB C
  • Mice
  • Isotope Labeling
  • Humans
  • ErbB Receptors
  • Drug Stability